<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39578604</PMID><DateCompleted><Year>2024</Year><Month>11</Month><Day>23</Day></DateCompleted><DateRevised><Year>2024</Year><Month>11</Month><Day>26</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Nov</Month><Day>22</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Different dynamics of soluble inflammatory mediators after clearance of respiratory SARS-CoV-2 versus blood-borne hepatitis C virus infections.</ArticleTitle><Pagination><StartPage>29013</StartPage><MedlinePgn>29013</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">29013</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-024-79909-8</ELocationID><Abstract><AbstractText>Viral infections can be acute or chronic, with the immune system pivotal in immunopathogenesis. The potential reversibility of inflammation post-viral elimination is of current interest. This study compares the dynamics of soluble inflammatory mediators (SIM) during and after respiratory infections with SARS-CoV-2 and blood-borne acute and chronic hepatitis C virus (HCV) infections. The study included patients with acute HCV (n&#x2009;=&#x2009;29), chronic HCV (n&#x2009;=&#x2009;54), and SARS-CoV-2 (n&#x2009;=&#x2009;39 longitudinal, n&#x2009;=&#x2009;103 cross-sectional), along with 30 healthy controls. Blood samples were collected at baseline, end of treatment/infection, and during follow-up (up to 9&#xa0;months). SIMs were quantified using the HD-SP-X Imaging and Analysis System&#x2122;. At baseline, SIM profiles in acute SARS-CoV-2 and HCV infections were significantly elevated compared with controls. During follow-up, SIM decline was less pronounced in acute and chronic HCV infections after successful therapy than in SARS-CoV-2 infections. Most SIM in the SARS-CoV-2 cohort normalized within 3&#xa0;months. In chronic HCV, SIM were higher in cirrhotic than noncirrhotic patients post-HCV elimination. Dynamics of SIM after viral elimination vary between blood-borne acute and chronic HCV infections and respiratory SARS-CoV-2 infections. Immunological imprints 3-9&#xa0;months after HCV elimination appear more pronounced than after SARS-CoV-2 infection.</AbstractText><CopyrightInformation>&#xa9; 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zeuzem</LastName><ForeName>Antonia</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School (MHH) OE 6810, Carl-Neuberg-Stra&#xdf;e 1, 30625, Hannover, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Individualised Infection Medicine (CiiM), A Joint Venture Between Helmholtz-Centre for Infection Research and Hannover Medical School, Feodor-Lynen-Stra&#xdf;e 11, 30625, Hannover, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Infection Research (DZIF), Partner Site Hannover-Braunschweig, Hannover, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>TWINCORE, Centre of Experimental and Clinical Infection Research, A Joint Venture Between Helmholtz-Centre for Infection Research and Hannover Medical School, Feodor-Lynen-Stra&#xdf;e 7, 30625, Hannover, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cluster of Excellence RESIST (EXC 2155), Hannover Medical School, Carl-Neuberg-Stra&#xdf;e 1, 30625, Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kumar</LastName><ForeName>Saumya Dileep</ForeName><Initials>SD</Initials><AffiliationInfo><Affiliation>Centre for Individualised Infection Medicine (CiiM), A Joint Venture Between Helmholtz-Centre for Infection Research and Hannover Medical School, Feodor-Lynen-Stra&#xdf;e 11, 30625, Hannover, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>TWINCORE, Centre of Experimental and Clinical Infection Research, A Joint Venture Between Helmholtz-Centre for Infection Research and Hannover Medical School, Feodor-Lynen-Stra&#xdf;e 7, 30625, Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oltmanns</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School (MHH) OE 6810, Carl-Neuberg-Stra&#xdf;e 1, 30625, Hannover, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Individualised Infection Medicine (CiiM), A Joint Venture Between Helmholtz-Centre for Infection Research and Hannover Medical School, Feodor-Lynen-Stra&#xdf;e 11, 30625, Hannover, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Infection Research (DZIF), Partner Site Hannover-Braunschweig, Hannover, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>TWINCORE, Centre of Experimental and Clinical Infection Research, A Joint Venture Between Helmholtz-Centre for Infection Research and Hannover Medical School, Feodor-Lynen-Stra&#xdf;e 7, 30625, Hannover, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cluster of Excellence RESIST (EXC 2155), Hannover Medical School, Carl-Neuberg-Stra&#xdf;e 1, 30625, Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Witte</LastName><ForeName>Moana</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School (MHH) OE 6810, Carl-Neuberg-Stra&#xdf;e 1, 30625, Hannover, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Individualised Infection Medicine (CiiM), A Joint Venture Between Helmholtz-Centre for Infection Research and Hannover Medical School, Feodor-Lynen-Stra&#xdf;e 11, 30625, Hannover, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Infection Research (DZIF), Partner Site Hannover-Braunschweig, Hannover, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>TWINCORE, Centre of Experimental and Clinical Infection Research, A Joint Venture Between Helmholtz-Centre for Infection Research and Hannover Medical School, Feodor-Lynen-Stra&#xdf;e 7, 30625, Hannover, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cluster of Excellence RESIST (EXC 2155), Hannover Medical School, Carl-Neuberg-Stra&#xdf;e 1, 30625, Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mischke</LastName><ForeName>Jasmin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School (MHH) OE 6810, Carl-Neuberg-Stra&#xdf;e 1, 30625, Hannover, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Individualised Infection Medicine (CiiM), A Joint Venture Between Helmholtz-Centre for Infection Research and Hannover Medical School, Feodor-Lynen-Stra&#xdf;e 11, 30625, Hannover, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Infection Research (DZIF), Partner Site Hannover-Braunschweig, Hannover, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>TWINCORE, Centre of Experimental and Clinical Infection Research, A Joint Venture Between Helmholtz-Centre for Infection Research and Hannover Medical School, Feodor-Lynen-Stra&#xdf;e 7, 30625, Hannover, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cluster of Excellence RESIST (EXC 2155), Hannover Medical School, Carl-Neuberg-Stra&#xdf;e 1, 30625, Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Drick</LastName><ForeName>Nora</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH), German Center for Lung Research (DZL), Hannover, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Respiratory Medicine and Infectious Diseases, Hannover Medical School (MHH), Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fuge</LastName><ForeName>Jan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH), German Center for Lung Research (DZL), Hannover, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Respiratory Medicine and Infectious Diseases, Hannover Medical School (MHH), Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pink</LastName><ForeName>Isabell</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH), German Center for Lung Research (DZL), Hannover, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Respiratory Medicine and Infectious Diseases, Hannover Medical School (MHH), Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tauwaldt</LastName><ForeName>Jan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School (MHH) OE 6810, Carl-Neuberg-Stra&#xdf;e 1, 30625, Hannover, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Individualised Infection Medicine (CiiM), A Joint Venture Between Helmholtz-Centre for Infection Research and Hannover Medical School, Feodor-Lynen-Stra&#xdf;e 11, 30625, Hannover, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Infection Research (DZIF), Partner Site Hannover-Braunschweig, Hannover, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>TWINCORE, Centre of Experimental and Clinical Infection Research, A Joint Venture Between Helmholtz-Centre for Infection Research and Hannover Medical School, Feodor-Lynen-Stra&#xdf;e 7, 30625, Hannover, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cluster of Excellence RESIST (EXC 2155), Hannover Medical School, Carl-Neuberg-Stra&#xdf;e 1, 30625, Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Debarry</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Centre for Individualised Infection Medicine (CiiM), A Joint Venture Between Helmholtz-Centre for Infection Research and Hannover Medical School, Feodor-Lynen-Stra&#xdf;e 11, 30625, Hannover, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>TWINCORE, Centre of Experimental and Clinical Infection Research, A Joint Venture Between Helmholtz-Centre for Infection Research and Hannover Medical School, Feodor-Lynen-Stra&#xdf;e 7, 30625, Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Illig</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Hannover Unified Biobank (HUB), Hannover Medical School (MHH), Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wedemeyer</LastName><ForeName>Heiner</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School (MHH) OE 6810, Carl-Neuberg-Stra&#xdf;e 1, 30625, Hannover, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Infection Research (DZIF), Partner Site Hannover-Braunschweig, Hannover, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cluster of Excellence RESIST (EXC 2155), Hannover Medical School, Carl-Neuberg-Stra&#xdf;e 1, 30625, Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maasoumy</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School (MHH) OE 6810, Carl-Neuberg-Stra&#xdf;e 1, 30625, Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Centre for Individualised Infection Medicine (CiiM), A Joint Venture Between Helmholtz-Centre for Infection Research and Hannover Medical School, Feodor-Lynen-Stra&#xdf;e 11, 30625, Hannover, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>TWINCORE, Centre of Experimental and Clinical Infection Research, A Joint Venture Between Helmholtz-Centre for Infection Research and Hannover Medical School, Feodor-Lynen-Stra&#xdf;e 7, 30625, Hannover, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cluster of Excellence RESIST (EXC 2155), Hannover Medical School, Carl-Neuberg-Stra&#xdf;e 1, 30625, Hannover, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine and Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kraft</LastName><ForeName>Anke R M</ForeName><Initials>ARM</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School (MHH) OE 6810, Carl-Neuberg-Stra&#xdf;e 1, 30625, Hannover, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Individualised Infection Medicine (CiiM), A Joint Venture Between Helmholtz-Centre for Infection Research and Hannover Medical School, Feodor-Lynen-Stra&#xdf;e 11, 30625, Hannover, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Infection Research (DZIF), Partner Site Hannover-Braunschweig, Hannover, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>TWINCORE, Centre of Experimental and Clinical Infection Research, A Joint Venture Between Helmholtz-Centre for Infection Research and Hannover Medical School, Feodor-Lynen-Stra&#xdf;e 7, 30625, Hannover, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cluster of Excellence RESIST (EXC 2155), Hannover Medical School, Carl-Neuberg-Stra&#xdf;e 1, 30625, Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cornberg</LastName><ForeName>Markus</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School (MHH) OE 6810, Carl-Neuberg-Stra&#xdf;e 1, 30625, Hannover, Germany. Cornberg.markus@mh-hannover.de.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Individualised Infection Medicine (CiiM), A Joint Venture Between Helmholtz-Centre for Infection Research and Hannover Medical School, Feodor-Lynen-Stra&#xdf;e 11, 30625, Hannover, Germany. Cornberg.markus@mh-hannover.de.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Infection Research (DZIF), Partner Site Hannover-Braunschweig, Hannover, Germany. Cornberg.markus@mh-hannover.de.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>TWINCORE, Centre of Experimental and Clinical Infection Research, A Joint Venture Between Helmholtz-Centre for Infection Research and Hannover Medical School, Feodor-Lynen-Stra&#xdf;e 7, 30625, Hannover, Germany. Cornberg.markus@mh-hannover.de.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cluster of Excellence RESIST (EXC 2155), Hannover Medical School, Carl-Neuberg-Stra&#xdf;e 1, 30625, Hannover, Germany. Cornberg.markus@mh-hannover.de.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>11</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018836">Inflammation Mediators</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018836" MajorTopicYN="Y">Inflammation Mediators</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006526" MajorTopicYN="N">Hepatitis C</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019698" MajorTopicYN="N">Hepatitis C, Chronic</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016174" MajorTopicYN="N">Hepacivirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Chemokines</Keyword><Keyword MajorTopicYN="N">Cirrhosis</Keyword><Keyword MajorTopicYN="N">Cytokines</Keyword><Keyword MajorTopicYN="N">Direct-acting antiviral</Keyword><Keyword MajorTopicYN="N">Hepatitis C virus</Keyword><Keyword MajorTopicYN="N">Immune mediators</Keyword><Keyword MajorTopicYN="N">Inflammation</Keyword><Keyword MajorTopicYN="N">Long-COVID</Keyword><Keyword MajorTopicYN="N">Proteomics</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2 infection</Keyword><Keyword MajorTopicYN="N">Sustained virological response</Keyword></KeywordList><CoiStatement>Declarations. Competing interests: The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>11</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>23</Day><Hour>11</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>23</Day><Hour>11</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>23</Day><Hour>2</Hour><Minute>11</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>11</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39578604</ArticleId><ArticleId IdType="pmc">PMC11584618</ArticleId><ArticleId IdType="doi">10.1038/s41598-024-79909-8</ArticleId><ArticleId IdType="pii">10.1038/s41598-024-79909-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Narasimhan, H., Wu, Y., Goplen, N. P. &amp; Sun, J. Immune determinants of chronic sequelae after respiratory viral infection. Sci. Immunol.7, eabm7996 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35857581</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis, H. E., McCorkell, L., Vogel, J. M. &amp; Topol, E. J. Long COVID: major findings, mechanisms and recommendations. Nat. Rev. Microbiol.21, 133&#x2013;146 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Altmann, D. M., Whettlock, E. M., Liu, S., Arachchillage, D. J. &amp; Boyton, R. J. The immunology of long COVID. Nat. Rev. Immunol.10.1038/s41577-023-00904-7 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37433988</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballering, A. V., van Zon, S. K. R., Olde Hartman, T. C., Rosmalen, J. G. M., Lifelines Corona Research Initiative. Persistence of somatic symptoms after COVID-19 in the Netherlands: an observational cohort study. Lancet400, 452&#x2013;461 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9352274</ArticleId><ArticleId IdType="pubmed">35934007</ArticleId></ArticleIdList></Reference><Reference><Citation>Oberfeld, B. et al. SnapShot: COVID-19. Cell181, 954-954.e1 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7190493</ArticleId><ArticleId IdType="pubmed">32413300</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang, C. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet395, 497&#x2013;506 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7159299</ArticleId><ArticleId IdType="pubmed">31986264</ArticleId></ArticleIdList></Reference><Reference><Citation>Fajgenbaum, D. C. &amp; June, C. H. Cytokine storm. N. Engl. J. Med.383, 2255&#x2013;2273 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7727315</ArticleId><ArticleId IdType="pubmed">33264547</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazza, M. G. et al. Persistent psychopathology and neurocognitive impairment in COVID-19 survivors: effect of inflammatory biomarkers at three-month follow-up. Brain Behav. Immun.94, 138&#x2013;147 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7903920</ArticleId><ArticleId IdType="pubmed">33639239</ArticleId></ArticleIdList></Reference><Reference><Citation>Komaroff, A. L. &amp; Lipkin, W. I. ME/CFS and Long COVID share similar symptoms and biological abnormalities: road map to the literature. Front. Med.10, 1187163 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10278546</ArticleId><ArticleId IdType="pubmed">37342500</ArticleId></ArticleIdList></Reference><Reference><Citation>Heim, M. H. &amp; Thimme, R. Innate and adaptive immune responses in HCV infections. J. Hepatol.61, S14-25 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25443342</ArticleId></ArticleIdList></Reference><Reference><Citation>Cornberg, M., Mischke, J., Kraft, A. R. &amp; Wedemeyer, H. Immunological scars after cure of hepatitis C virus infection: long-HepC?. Curr. Opin. Immunol.82, 102324 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37043890</ArticleId></ArticleIdList></Reference><Reference><Citation>Manns, M. P. &amp; Maasoumy, B. Breakthroughs in hepatitis C research: from discovery to cure. Nat. Rev. Gastroenterol. Hepatol.19, 533&#x2013;550 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9122245</ArticleId><ArticleId IdType="pubmed">35595834</ArticleId></ArticleIdList></Reference><Reference><Citation>Cacoub, P. &amp; Saadoun, D. Extrahepatic manifestations of chronic HCV infection. N. Engl. J. Med.384, 1038&#x2013;1052 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33730456</ArticleId></ArticleIdList></Reference><Reference><Citation>Dirks, M. et al. Persistent neuropsychiatric impairment in HCV patients despite clearance of the virus?!. J. Viral Hepat.24, 541&#x2013;550 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28117537</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohlendorf, V. et al. Only partial improvement in health-related quality of life after treatment of chronic hepatitis C virus infection with direct acting antivirals in a real-world setting-results from the German Hepatitis C-Registry (DHC-R). J. Viral Hepat.28, 1206&#x2013;1218 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34003549</ArticleId></ArticleIdList></Reference><Reference><Citation>Aregay, A. et al. Systemic inflammation and immune cell phenotypes are associated with neuro-psychiatric symptoms in patients with chronic inflammatory liver diseases. Liver Int.38, 2317&#x2013;2328 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29710425</ArticleId></ArticleIdList></Reference><Reference><Citation>Radkowski, M. et al. Cytokine profile and viral diversity in the early seronegative stage of community-acquired hepatitis C virus (HCV) infection. Sci. Rep.13, 20045 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10654698</ArticleId><ArticleId IdType="pubmed">37973814</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiegand, S. B. et al. Soluble immune markers in the different phases of chronic hepatitis B virus infection. Sci. Rep.9, 14118 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6773856</ArticleId><ArticleId IdType="pubmed">31575964</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahat, R. K. et al. The dynamics of inflammatory markers in coronavirus disease-2019 (COVID-19) patients: A systematic review and meta-analysis. Clin. Epidemiol. Glob. Health11, 100727 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7979575</ArticleId><ArticleId IdType="pubmed">33778183</ArticleId></ArticleIdList></Reference><Reference><Citation>Maa&#xdf;, H. et al. Serum cytokine dysregulation signatures associated with COVID-19 outcomes in high mortality intensive care unit cohorts across pandemic waves and variants. Sci. Rep.14, 13605 (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11176334</ArticleId><ArticleId IdType="pubmed">38871772</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang, C. et al. Multi-cohort study on cytokine and chemokine profiles in the progression of COVID-19. Sci. Rep.14, 10324 (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11074324</ArticleId><ArticleId IdType="pubmed">38710800</ArticleId></ArticleIdList></Reference><Reference><Citation>van Meijgaarden, K. E. et al. Longitudinal soluble marker profiles reveal strong association between cytokine storms resulting from macrophage activation and disease severity in COVID-19 disease. Sci. Rep.14, 12882 (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11153563</ArticleId><ArticleId IdType="pubmed">38839796</ArticleId></ArticleIdList></Reference><Reference><Citation>Deterding, K. et al. Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 monoinfection (HepNet Acute HCV IV): an open-label, single-arm, phase 2 study. Lancet Infect Dis.17, 215&#x2013;222 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28029529</ArticleId></ArticleIdList></Reference><Reference><Citation>Maasoumy, B. et al. Sofosbuvir plus velpatasvir for 8 weeks in patients with acute hepatitis C: The HepNet acute HCV-V study. JHEP Rep.5, 100650 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9957891</ArticleId><ArticleId IdType="pubmed">36852107</ArticleId></ArticleIdList></Reference><Reference><Citation>Racanelli, V. &amp; Rehermann, B. The liver as an immunological organ. Hepatology43, S54-62 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16447271</ArticleId></ArticleIdList></Reference><Reference><Citation>Bosch, M. et al. A liver immune rheostat regulates CD8 T cell immunity in chronic HBV infection. Nature10.1038/s41586-024-07630-7 (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11269190</ArticleId><ArticleId IdType="pubmed">38987588</ArticleId></ArticleIdList></Reference><Reference><Citation>Albillos, A., Lario, M. &amp; &#xc1;lvarez-Mon, M. Cirrhosis-associated immune dysfunction: distinctive features and clinical relevance. J. Hepatol.61, 1385&#x2013;1396 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25135860</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiedermann, M. et al. Evidence for positive long- and short-term effects of vaccinations against COVID-19 in wearable sensor metrics. PNAS Nexus2, pgad223 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10368316</ArticleId><ArticleId IdType="pubmed">37497048</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinmetz, A. et al. Longitudinal clinical features of post-COVID-19 patients-symptoms, fatigue and physical function at 3- and 6-month follow-up. J. Clin. Med.12, 3966 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10299126</ArticleId><ArticleId IdType="pubmed">37373660</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai, Y.-J. et al. Biomarkers in long COVID-19: A systematic review. Front. Med.10, 1085988 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9895110</ArticleId><ArticleId IdType="pubmed">36744129</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, Z. et al. Multi-omics integration reveals only minor long-term molecular and functional sequelae in immune cells of individuals recovered from COVID-19. Front. Immunol.13, 838132 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9022455</ArticleId><ArticleId IdType="pubmed">35464396</ArticleId></ArticleIdList></Reference><Reference><Citation>Bagheri-Hosseinabadi, Z., Kaeidi, A., Rezvani, M., Taghipour Khaje Sharifi, G. &amp; Abbasifard, M. Evaluation of the serum levels of CCL2, CCL3, and IL-29 after first and second administrations of the COVID-19 vaccine (Oxford-AstraZeneca). Immunobiology229, 152789 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38290406</ArticleId></ArticleIdList></Reference><Reference><Citation>Nielsen, N. M., Spiliopoulos, L., Hansen, J. V., Videbech, P. &amp; Hviid, A. SARS-CoV-2 infection and risk of postacute psychiatric and neurologic diagnoses: a nationwide Danish cohort study. Neurology102, e208113 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38382013</ArticleId></ArticleIdList></Reference><Reference><Citation>Jakobsen, K. D., O&#x2019;Regan, E., Svalgaard, I. B. &amp; Hviid, A. Machine learning identifies risk factors associated with long-term sick leave following COVID-19 in Danish population. Commun. Med.3, 188 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10733276</ArticleId><ArticleId IdType="pubmed">38123739</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>